Drts.O

Alpha Tau Medical Ltd maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds $12.2 million in cash and equivalents against total assets of $105.7 million and total liabilities of $28.6 million. Despite the absence of debt, the company faces liquidity pressure, evidenced by negative operating cash flow of -$26.7 million and a low liquidity risk assessment. The market capitalization stands at approximately $1.04 billion, implying a significant premium over the book value of equity, which is $77.1 million.

Profitability metrics are deeply negative, with a return on equity of -55.3% and a return on assets of -40.4%. The company reported an operating loss of -$42.3 million and a net loss of -$42.6 million for the latest period. The price-to-book ratio is elevated at 13.5, reflecting market expectations for future growth rather than current earnings power. The EV/EBITDA ratio is negative (-24.33), consistent with the company's current unprofitable status. No cohort median data is available to benchmark these profitability metrics against industry peers.

Segment and geographic revenue breakdowns are not provided in the available data. Consequently, specific revenue concentration risks or regional exposure details cannot be quantified. The analysis relies solely on consolidated financial figures, which show a total asset base of $105.7 million supporting the company's operations.

Growth trajectory analysis is limited by the absence of historical period data. Without multi-year revenue or net income trends, it is not possible to assess the directionality of revenue growth or the consistency of losses over time. The current snapshot shows a single period of significant operating losses, but the trend leading to this position is not visible in the provided inputs.

Risk assessment indicates low liquidity and low dilution risk. The key flags section notes no immediate filing-based liquidity or dilution flags. The absence of debt mitigates credit risk, but the negative operating cash flow of -$26.7 million suggests reliance on existing cash reserves or potential future equity financing to sustain operations. The dilution risk is currently assessed as low, with basic and diluted shares outstanding being identical at 88.0 million.

Recent observations include analyst estimates with a mean price target of $14.20 and a median target of $15.00, suggesting a potential upside from the current market price of $11.83. The mean recommendation is 1.80, indicating a buy bias among covering analysts. News events primarily reflect internal system reconciler activities rather than external corporate developments or filing disclosures.

Operating income −43,0% YoY; Net income −163,9% YoY.

• ▍Operating income −43,0% YoY
• ▍Net income −163,9% YoY

Operating income −22,7% YoY; Net income −28,1% YoY.

• ▍Operating income −22,7% YoY
• ▍Net income −28,1% YoY

Operating income −29,4% YoY; Net income −68,8% YoY.

• ▍Operating income −29,4% YoY
• ▍Net income −68,8% YoY

Operating income −6,6% YoY; Net income −37,2% YoY.

• ▍Operating income −6,6% YoY
• ▍Net income −37,2% YoY

Operating income -$9.3M.

• ▍Operating income -$9.3M

Operating income -$10.3M.

• ▍Operating income -$10.3M

Operating income -$8.3M.

• ▍Operating income -$8.3M

Operating income -$9.1M.

• ▍Operating income -$9.1M

Operating income −17,3% YoY; Net income −34,3% YoY.

• ▍Operating income −17,3% YoY
• ▍Net income −34,3% YoY
• ▍Free cash flow −44,4% YoY

Operating income −1,0% YoY; Net income −8,9% YoY.

• ▍Operating income −1,0% YoY
• ▍Net income −8,9% YoY
• ▍Free cash flow +4,6% YoY

Operating income −11,0% YoY; Net income +13,6% YoY.

• ▍Operating income −11,0% YoY
• ▍Net income +13,6% YoY
• ▍Free cash flow −2,4% YoY

Operating income −133,0% YoY; Net income −23,8% YoY.

• ▍Operating income −133,0% YoY
• ▍Net income −23,8% YoY
• ▍Free cash flow −14,5% YoY